CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel Sells $120,897.00 in Stock

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) General Counsel James R. Kasinger sold 2,850 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total transaction of $120,897.00. Following the sale, the general counsel now owns 77,530 shares of the company's stock, valued at $3,288,822.60. The trade was a 3.55 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

CRISPR Therapeutics Trading Up 0.3 %

CRSP traded up $0.13 on Friday, hitting $42.12. The company had a trading volume of 1,422,025 shares, compared to its average volume of 2,217,680. The firm has a market cap of $3.61 billion, a P/E ratio of -9.64 and a beta of 1.77. The company's fifty day moving average price is $43.03 and its 200 day moving average price is $45.63. CRISPR Therapeutics AG has a 1 year low of $36.52 and a 1 year high of $75.91.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Remove Ads

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on CRSP shares. StockNews.com upgraded CRISPR Therapeutics to a "sell" rating in a report on Thursday, February 13th. JMP Securities reaffirmed a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Barclays raised their target price on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 12th. Evercore ISI upgraded shares of CRISPR Therapeutics from an "in-line" rating to an "outperform" rating and increased their price objective for the company from $60.00 to $99.00 in a research note on Friday, February 14th. Finally, Stifel Nicolaus lowered their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating for the company in a report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of "Hold" and an average target price of $73.11.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of institutional investors have recently modified their holdings of the company. Boston Family Office LLC boosted its holdings in CRISPR Therapeutics by 2.2% during the 3rd quarter. Boston Family Office LLC now owns 9,763 shares of the company's stock valued at $459,000 after acquiring an additional 213 shares during the period. Bedell Frazier Investment Counselling LLC raised its stake in shares of CRISPR Therapeutics by 0.8% in the third quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company's stock valued at $1,238,000 after acquiring an additional 218 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of CRISPR Therapeutics by 1.9% in the third quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company's stock valued at $586,000 after acquiring an additional 231 shares in the last quarter. Intellectus Partners LLC boosted its holdings in CRISPR Therapeutics by 3.6% in the fourth quarter. Intellectus Partners LLC now owns 7,131 shares of the company's stock valued at $281,000 after purchasing an additional 250 shares during the period. Finally, Farrow Financial Inc. grew its stake in CRISPR Therapeutics by 1.4% during the 4th quarter. Farrow Financial Inc. now owns 20,097 shares of the company's stock worth $777,000 after purchasing an additional 270 shares in the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.